aTYR PHARMA (ATYR) Accumulated Expenses (2014 - 2026)

aTYR PHARMA (ATYR) has 13 years of Accumulated Expenses data on file, last reported at $7.5 million in Q1 2026.

• Quarterly Accumulated Expenses fell 5.14% year-over-year to $7.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.5 million (down 5.14% YoY) and the FY2025 annual result came in at $9.8 million, up 4.25% from the prior year.
• Accumulated Expenses declined to $7.5 million in Q1 2026, from $9.8 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $10.8 million in Q2 2023 to a low of $2.7 million in Q4 2023.
• A 5-year average of $8.0 million and a median of $9.0 million in 2024 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Accumulated Expenses slumped 30.51% — and 2024, when it jumped 247.08%.
• Tracing ATYR's Accumulated Expenses over 5 years: stood at $2.8 million in 2022, then dropped by 2.7% to $2.7 million in 2023, then jumped by 247.08% to $9.4 million in 2024, then grew by 4.25% to $9.8 million in 2025, then fell by 23.83% to $7.5 million in 2026.
• The last three Accumulated Expenses figures came in at $7.5 million (Q1 2026), $9.8 million (Q4 2025), and $10.2 million (Q3 2025), per Business Quant data.